Dongfeng Qu to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications Dongfeng Qu has written about Xenograft Model Antitumor Assays.
Connection Strength
0.168
-
Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer. Int J Cancer. 2018 09 01; 143(5):1162-1175.
Score: 0.035
-
(Z)-3,5,4'-Trimethoxystilbene Limits Hepatitis C and Cancer Pathophysiology by Blocking Microtubule Dynamics and Cell-Cycle Progression. Cancer Res. 2016 08 15; 76(16):4887-96.
Score: 0.030
-
Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism. Oncotarget. 2015 Nov 10; 6(35):37200-15.
Score: 0.029
-
XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism. Cancer Lett. 2014 Aug 28; 351(1):151-61.
Score: 0.026
-
DCLK1 regulates pluripotency and angiogenic factors via microRNA-dependent mechanisms in pancreatic cancer. PLoS One. 2013; 8(9):e73940.
Score: 0.025
-
Nanoparticle-based delivery of siDCAMKL-1 increases microRNA-144 and inhibits colorectal cancer tumor growth via a Notch-1 dependent mechanism. J Nanobiotechnology. 2011 Sep 19; 9:40.
Score: 0.022